NCT02405338View on ClinicalTrials.gov

DC Vaccination for Post-remission Therapy in AML

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL

WT1/PRAME vaccination

Trial Locations (1)

0424

Oslo University Hospital, Rikshospitalet, Oslo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Medigene AG

INDUSTRY

NCT02405338 - DC Vaccination for Post-remission Therapy in AML | Biotech Hunter | Biotech Hunter